CSL (HAM:CSJ) ROIC %: 8.44% (As of Dec. 2025)


HAM:CSJ CSL Ltd HAM:CSJ
73 GF Score
Price €68.23
GF Value €170.71
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL ROIC %?

CSL HAM:CSJ +0.07% 73 ROIC % is 8.44% as of Dec. 2025. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €170.71 (Significantly Undervalued). The stock has 7 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. CSL's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2025 was 8.44%.

As of today (2026-06-24), CSL's WACC % is 6.35%. CSL's ROIC % is 4.21% (calculated using TTM income statement data). CSL earns returns that do not match up to its cost of capital. It will destroy value as it grows.


CSL  (HAM:CSJ) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, CSL's WACC % is 6.35%. CSL's ROIC % is 4.21% (calculated using TTM income statement data). CSL earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


CSL ROIC % Related Terms


CSL ROIC % Historical Data

* Premium members only.

The historical data trend for CSL's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL ROIC % Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.86 12.85 7.25 6.89 7.21

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.19 9.56 4.01 0.00 8.44

HAM:CSJ vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, CSL's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's ROIC % distribution charts can be found below:

* The bar in red indicates where CSL's ROIC % falls into.


HAM:CSJ
73GF Score
CSL Ltd HAM:CSJ
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL ROIC % Calculation

CSL's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jun. 2025 is calculated as:

ROIC % (A: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2024 ) + Invested Capital (A: Jun. 2025 ))/ count )
=2565.453 * ( 1 - 15.79% )/( (30675.58 + 29292.462)/ 2 )
=2160.3679713/29984.021
=7.21 %

where

Invested Capital(A: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=35322.438 - 3107.505 - ( 1539.353 - max(0, 4598.55 - 10003.472+1539.353))
=30675.58

Invested Capital(A: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=34163.268 - 3000.687 - ( 1870.119 - max(0, 4174.605 - 10273.95+1870.119))
=29292.462

CSL's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2025 is calculated as:

ROIC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=3252.032 * ( 1 - 24.74% )/( (29292.462 + 28682.444)/ 2 )
=2447.4792832/28987.453
=8.44 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=34163.268 - 3000.687 - ( 1870.119 - max(0, 4174.605 - 10273.95+1870.119))
=29292.462

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=32368.308 - 2708.034 - ( 977.83 - max(0, 3935.232 - 10119.046+977.83))
=28682.444

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 8.44% mean?
CSL (HAM:CSJ) has a ROIC % of 8.44% as of Dec. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on CSL and its competitors.
Is CSL's ROIC % too high?
CSL's current ROIC % is 8.44%. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's ROIC % compare to VRTX and REGN?
CSL's ROIC % of 8.44% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on CSL and its competitors. CSL's current ROIC % is 8.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €170.71, compared to a current price of €68.23 — trading 60% below its estimated fair value. The current ROIC % is 8.44%. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For CSL (HAM:CSJ), the current ROIC % is 8.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (HAM:CSJ) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of €68.23 is trading 60% below its estimated GF Value™ of €170.71. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for HAM:CSJ:

  • ROIC %: 8.44%
  • GF Value™: €170.71 vs. price of €68.23 (60% below fair value)
  • GF Score™: 73/100 with 7 warning signs

No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for HAM:CSJ

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.23
Price
€170.71
GF Value